银屑病关节炎生物制剂治疗的持续性:来自大型医院纵向队列的数据
该研究对多伦多队列中2000年1月1日至2020年7月7日期间启动生物制剂治疗的571例银屑病关节炎患者进行回顾性分析,评估药物持续使用概率。结果显示,certolizumab作为第一种生物制剂时3年持续概率最高,而作为第二种药物时药物生存率最低;抑郁和/或焦虑与全因停药率升高相关(RR 1.68,P=0.01),高等教育与较低停药率相关(RR 0.65,P=0.03)。
要点
- certolizumab作为第一种生物制剂时3年持续概率最高,作为第二种药物时药物生存率最低。
- 抑郁和/或焦虑与全因停药率升高相关(RR 1.68,P=0.01)。
- 较高教育水平与较低全因停药率相关(RR 0.65,P=0.03)。
核心结论
- 生物制剂的持续使用取决于其作为第一种还是第二种治疗。
- 抑郁和焦虑、较高的压痛关节计数以及较大年龄导致停药。
研究设计与样本
- 对多伦多队列中2000年1月1日至2020年7月7日期间启动生物制剂治疗的571例银屑病关节炎患者进行回顾性分析。
- 采用非参数方法估计药物持续使用概率,使用Cox回归模型分析第一和第二种治疗的中断时间,使用带gamma frailty的半参数失效时间模型分析连续多次生物制剂治疗的中断。
主要发现
- 作为第一种生物制剂治疗时,certolizumab的3年持续概率最高,而白细胞介素-17抑制剂概率最低。
- 作为第二种药物时,即使考虑选择偏倚,certolizumab的药物生存率最低。
- 抑郁和/或焦虑与全因停药率升高相关(RR 1.68,P=0.01),较高教育与较低停药率相关(RR 0.65,P=0.03)。
- 在涵盖多次生物制剂疗程的分析中,较高的压痛关节计数与全因停药率升高相关(RR 1.02,P=0.01)。
- 首次治疗开始时年龄较大与副作用停药率升高相关(RR 1.03,P=0.01),而肥胖具有保护作用(RR 0.56,P=0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the trends in biologics use at a specialized center over a period of 20 years. METHODS: We performed a retrospective analysis of 571 patients diagnosed with psoriatic arthritis enrolled in the Toronto cohort who initiated biologic therapy between January 1, 2000, and July 7, 2020. The probability of drug persistence over time was estimated nonparametrically. The time to discontinuation of first and second treatment was analyzed using Cox regression models, whereas a semiparametric failure time model with a gamma frailty was used to analyze the discontinuation of treatment over successive administrations of biologic therapy. RESULTS: The highest 3-year persistence probability was observed with certolizumab when used as first biologic treatment, while interleukin-17 inhibitors had the lowest probability. However, when used as second medication, certolizumab had the lowest drug survival even when accounting for selection bias. Depression and/or anxiety were associated with a higher rate of drug discontinuation due to all causes (relative risk [RR] 1.68, P = 0.01), while having higher education was associated with lower rates (RR 0.65, P = 0.03). In the analysis accommodating multiple courses of biologics, a higher tender joint count was associated with a higher rate of discontinuation due to all causes (RR 1.02, P = 0.01). Older age at the start of first treatment was associated with a higher rate of discontinuation due to side effects (RR 1.03, P = 0.01), while obesity had a protective role (RR 0.56, P = 0.05). CONCLUSION: Persistence in taking biologics depends on whether the biologic was used as first or second treatment. Depression and anxiety, higher tender joint count, and older age lead to drug discontinuation.
引用
- Rida MA, Lee KA, Chandran V, et al. Persistence of Biologics in the Treatment of Psoriatic Arthritis: Data From a Large Hospital-Based Longitudinal Cohort. Arthritis Care Res (Hoboken). 2023. PMID: 36913183. doi:10.1002/acr.25112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。